US Stock MarketDetailed Quotes
SPRY ARS Pharmaceuticals
- 14.510
- -0.020-0.14%
Close Nov 29 13:00 ET
- 14.510
- 0.0000.00%
Post 17:01 ET
1.41BMarket Cap-29020P/E (TTM)
14.900High14.390Low383.07KVolume14.520Open14.530Pre Close5.58MTurnover0.84%Turnover RatioLossP/E (Static)97.19MShares18.51052wk High7.02P/B664.82MFloat Cap4.94052wk Low--Dividend TTM45.82MShs Float63.410Historical High--Div YieldTTM3.51%Amplitude2.550Historical Low14.560Avg Price1Lot Size
ARS Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -13.35%-14.47M | 56.33%-7.28M | 46.01%-6.71M | -47.88%-59.27M | 15.09%-17.41M | -124.62%-12.76M | -139.02%-16.67M | -79.48%-12.43M | -128.22%-40.08M | -20.5M |
| Net income from continuing operations | -28.67%-19.13M | 27.94%-12.52M | 31.21%-10.29M | -56.75%-54.37M | 50.32%-7.17M | -125.82%-14.87M | -170.56%-17.37M | -106.36%-14.96M | -71.33%-34.68M | ---14.43M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 3,600.00%140K | --143K |
| Depreciation and amortization | -17.28%-1.81M | -8.89%-1.89M | -10.06%-1.97M | -2,233.23%-6.81M | -683.61%-1.75M | -22,085.71%-1.54M | -4,581.08%-1.73M | -3,678.00%-1.79M | 49.77%319K | --299K |
| Other non cash items | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --1.06M | --931K |
| Change In working capital | 178.32%2.88M | 1,021.79%3.76M | 7.97%2.24M | 42.52%-7.33M | 11.75%-10.77M | 162.18%1.03M | 135.04%335K | 17,158.33%2.07M | -3,482.58%-12.75M | ---12.2M |
| -Change in prepaid assets | -472.73%-504K | 462.10%697K | 94.83%867K | -20.99%-1.44M | -60.74%-1.92M | -163.77%-88K | 155.36%124K | 383.70%445K | -201.11%-1.19M | ---1.19M |
| -Change in payables and accrued expense | 286.03%4.34M | 1,268.75%3.07M | -71.74%1.34M | 73.00%-2.78M | 22.25%-8.88M | 30.85%1.12M | 183.90%224K | 771.06%4.76M | -1,155.95%-10.29M | ---11.42M |
| -Change in other working capital | -1,033.33%-34K | 61.54%-5K | 100.80%25K | -143.10%-3.12M | -67.47%27K | 98.91%-3K | 97.20%-13K | -400.00%-3.13M | 48.74%-1.28M | --83K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -13.35%-14.47M | 56.33%-7.28M | 46.01%-6.71M | -47.88%-59.27M | 15.09%-17.41M | -124.62%-12.76M | -139.02%-16.67M | -79.48%-12.43M | -128.22%-40.08M | ---20.5M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 136.06%16.82M | -128.12%-12.65M | 92.37%-8.51M | -43,709.05%-87.18M | 20,765.87%26.04M | -155,376.67%-46.64M | 204,509.09%44.97M | -531,071.43%-111.55M | -261.82%-199K | -126K |
| Net PPE purchase and sale | -225.58%-140K | -26.67%-38K | 56.99%-83K | 12.06%-175K | 172.22%91K | -43.33%-43K | -36.36%-30K | -819.05%-193K | -261.82%-199K | ---126K |
| Net investment purchase and sale | 141.76%19.46M | -128.02%-12.61M | 92.43%-8.43M | ---87.01M | --25.95M | ---46.6M | --45M | ---111.35M | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 136.06%16.82M | -128.12%-12.65M | 92.37%-8.51M | -43,709.05%-87.18M | 20,765.87%26.04M | -155,376.67%-46.64M | 204,509.09%44.97M | -531,071.43%-111.55M | -261.82%-199K | ---126K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -26.17%680K | -80.90%545K | -80.44%258K | -96.38%6.9M | -99.07%1.81M | 159.19%921K | 558.11%2.85M | 245.26%1.32M | 258.80%190.73M | 193.82M |
| Net issuance payments of debt | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | -377.77%-8.68M | ---5.95M |
| Proceeds from stock option exercised by employees | -26.17%680K | -80.90%545K | -80.44%258K | 1,110.35%6.9M | 537.81%1.81M | --921K | 894.43%2.85M | --1.32M | 237.28%570K | --283K |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --198.84M | --199.49M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -26.17%680K | -80.90%545K | -80.44%258K | -96.38%6.9M | -99.07%1.81M | 159.19%921K | 558.11%2.85M | 245.26%1.32M | 258.80%190.73M | --193.82M |
| Net cash flow | ||||||||||
| Beginning cash position | -69.23%36.63M | -36.26%56.01M | -66.29%70.97M | 250.50%210.52M | 62.19%60.53M | 166.91%119.02M | 68.29%87.86M | 250.50%210.52M | 144.95%60.06M | --37.32M |
| Current changes in cash | 105.18%3.03M | -162.21%-19.38M | 87.80%-14.97M | -192.75%-139.55M | -93.97%10.44M | -704.69%-58.49M | 508.91%31.16M | -1,461.70%-122.66M | 323.32%150.46M | --173.2M |
| End cash Position | -34.49%39.66M | -69.23%36.63M | -36.26%56.01M | -66.29%70.97M | -66.29%70.97M | 62.19%60.53M | 166.91%119.02M | 68.29%87.86M | 250.50%210.52M | --210.52M |
| Free cash flow | -14.06%-14.61M | 56.18%-7.32M | 46.18%-6.79M | -47.58%-59.44M | 16.05%-17.31M | -124.19%-12.81M | -138.69%-16.7M | -81.72%-12.62M | -128.64%-40.28M | ---20.62M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data